Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.65 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.65 |
| ▸ | PDE8A | O60658 | 3/20 | 0.65 |
| ▸ | HPGDS | O60760 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100260 | 1.00 | PDE7A (0.65) | PDE7APDE7BPDE8AHPGDSCYP3A4 | |
| SCHEMBL101124 | 0.92 | PDE7A (0.64) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL30837924 | 0.92 | PDE7A (0.64) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL100396 | 0.90 | PDE7A (0.53) | PDE7APDE7BPDE8AHPGDSOPRM1 | |
| SCHEMBL32681322 | 0.90 | PDE7A (0.53) | PDE7APDE7BPDE8AHPGDSOPRM1 | |
| SCHEMBL100353 | 0.89 | PDE7A (0.71) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL30837769 | 0.89 | PDE7A (0.71) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL100882 | 0.89 | PDE7A (0.69) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL30837969 | 0.89 | PDE7A (0.69) | PDE7APDE7BPDE8ACYP3A4CYP2D6 | |
| SCHEMBL100108 | 0.86 | PDE7A (0.66) | PDE7APDE7BPDE8ACYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.